Galena Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 91   

Articles published

GALE 1.99 -0.07 (-3.40%)
price chart
Why Galena Biopharma, Inc. Stock Crashed By 52% in 2014
The overall market may be on pace to deliver solid gains for investors in 2014, but shareholders in Galena Biopharma (NASDAQ: GALE ) can do nothing but shake their head in disappointment with their stock down 52% for the year.
Related articles »  
Galena Biopharma Announces Release of Special Committee Report and ...
Galena Biopharma, Inc. GALE, -2.35% today announced the release of a report prepared by the former Special Committee of Galena's Board of Directors regarding the Company's 2012-2014 market visibility campaigns and the sale of shares by insiders in the ...
Related articles »  
Mid-Day Buzzers � Galena Biopharma Inc (NASDAQ:GALE),Silver Standard ...
Manhattan, NY- October 01, 2014 - (Techsonian) - Galena Biopharma Inc (NASDAQ:GALE) announced the release of a report prepared by the former Special Committee of Galena's Board of Directors regarding the Company's 2012-2014 market visibility ...
Galena Biopharma to Present at the Rodman & Renshaw 16th Annual Global ...
Galena Biopharma, Inc. GALE, +0.47% a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W.
Related articles »  
Trader's Alert - Galena Biopharma Inc (NASDAQ:GALE), Nike Inc (NYSE:NKE ...
Galena Biopharma Inc (NASDAQ:GALE) the biopharmaceutical company, late Thursday released a report by the former special committee of its board saying there is no credible basis for finding that the company or insiders violated applicable law or that ...
Galena Biopharma Doses First Patient in GALE-401 (Anagrelide Controlled ...
PORTLAND, Ore., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full ...
Galena Biopharma Says Doses First Patient In GALE-401 Phase 2 Clinical Trial  RTT News
Related articles »  
Short Interest in Galena Biopharma Decreases By 5.0% (GALE)
Galena Biopharma, Inc (NASDAQ:GALE), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using ...
Related articles »  
Hot Watch List: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Galena ...
Based on discussions with the U.S. Food and Drug Administration (FDA) and pending a successful development program, Galena would pursue approval via the 505(b)(2) regulatory pathway.
Momentum Stocks: MannKind Corp. (NASDAQ:MNKD), Arotech Corporation ...  Markets Insider
Related articles »  
Eye Catching Stocks: Biogen Idec Inc. (NASDAQ:BIIB), Galena Biopharma, Inc ...
Biogen Idec Inc. (NASDAQ:BIIB) ended the last trading day at $332.08. Company weekly volatility is calculated as 2.59%and price to cash ratio as 49.85.
Related articles »  
Stocks in Focus Galena Biopharma (NASDAQ:GALE), American Airlines Group ...
On September 9, Galena Biopharma Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, announced the ...